Preauricular sinus, a congenital malformation resulting from incomplete fusion of the first and second branchial arches, is a relatively common condition with a reported prevalence of 0.1% to 0.9%. While mostly asymptomatic, it can lead to abscess formation when infected. We present a unique case of a neglected preauricular sinus abscess that extended to the scalp, causing significant complications. The report discusses the clinical presentation, diagnostic approach, treatment modalities, and potential complications associated with this unusual and severe presentation. Prompt and appropriate management, combined with conservative treatment and surgical intervention, led to successful outcomes. This case highlights the importance of recognizing potential risks and implementing a systematic approach in managing recurrent preauricular sinus abscesses.

Colorectal cancer is the third most common cancer in Korea and the third leading cause of death from cancer. Treatment outcomes for colon cancer are steadily improving due to national health screening programs with advances in diagnostic methods, surgical techniques, and therapeutic agents.. The Korea Colon Cancer Multidisciplinary (KCCM) Committee intends to provide professionals who treat colon cancer with the most up-to-date, evidence-based practice guidelines to improve outcomes and help them make decisions that reflect their patients’ values and preferences. These guidelines have been established by consensus reached by the KCCM Guideline Committee based on a systematic literature review and evidence synthesis and by considering the national health insurance system in real clinical practice settings. Each recommendation is presented with a recommendation strength and level of evidence based on the consensus of the committee.

Background and Objectives: We compared the efficacy and safety of human bone marrow-derived mesenchymal stem cells (hBMSC), delivered at different doses and via different injection routes in an animal model of chronic kidney disease. Methods: and Results: A total of ninety 12-week-old rats underwent 5/6 nephrectomy and randomized among nine groups: sham, renal artery control (RA-C), tail vein control (TV-C), renal artery low dose (RA-LD) (0.5×10 6 cells), renal artery moderate dose (RA-MD) (1.0×10 6 cells), renal artery high dose (RA-HD) (2.0×10 6 cells), tail vein low dose (TV-LD) (0.5×10 6 cells), tail vein moderate dose (TV-MD) (1.0×10 6 cells), and tail vein high dose (TV-HD) (2.0×10 6 cells). Renal function and mortality of rats were evaluated after hBMSC injection. Serum blood urea nitrogen was significantly lower in the TV-HD group at 2 weeks (p＜0.01), 16 weeks (p＜0.05), and 24 weeks (p＜0.01) than in the TV-C group, as determined by one-way ANOVA. Serum creatinine was significantly lower in the TV-HD group at 24 weeks (p＜0.05). At 8 weeks, creatinine clearance was significantly higher in the TV-MD and TV-HD groups (p＜0.01, p＜0.05) than in the TV-C group. In the safety evaluation, we observed no significant difference among the groups. Conclusions Our findings confirm the efficacy and safety of high dose (2×10 6 cells) injection of hBMSC via the tail vein.

Purpose: In the case of a chronically unhealed 3rd or 4th degree burn, the lesion may involve the deep structures, and may be deeper and wider than what is visible on gross examination. Deep burns with severe inflammation may result in pus collection.Surgical unroofing and drainage are the treatments of choice for improving the patient's general condition. Before surgery, accurately identifying the range of the lesion is important for planning. Preoperative imaging scans such as magnetic resonance imaging (MRI) and computed tomography (CT) help identify involved deep structures and check the range and presence of pus collections. Methods: A retrospective review was performed from 2021 to 2023 on a total of nine cases with severely infected deep burns who were checked with preoperative MRI or CT to confirm the range of lesions and pus collection in our hospital. The patients were chosen based on whether or not there was pus discharge, the inflammation levels, and a fever above 38 degrees. Results: Preoperative imaging scans were crucial for determining the timing of surgery and establishing its scope and plan. All nine patients were able to unroof the entire abscess in one surgery without trial and error. After surgery, the inflammation was reduced, and a clean wound bed was observed. Conclusion In this report, we discuss the efficacy of preoperative MRI and CT examinations for identifying deep burns and extensive pus collection findings that are difficult to identify on the gross examination when planning surgical management.

Endochondral pseudocyst of the ear is a rare, benign, non-inflammatory cystic disease. It is known that there are a variety of treatment methods for pseudocyst, which is mainly common in the scaphoid or triangular fossa of the ear. Pseudocyst formation is prevalent in the residual cavity of the ear. So, to prevent a recurrence, a surgical approach is also required, but management through compression is necessary after surgery. Applying a cube magnet to the lesion to press provides patient convenience and facilitates continuous management.

Background/Aims: We evaluated the feasibility and long-term efficacy of the combination of cytarabine, idarubicin, and all-trans retinoic acid (ATRA) for treating patients with newly diagnosed acute promyelocytic leukemia (APL). Methods: We included 87 patients with newly diagnosed acute myeloid leukemia and a t(15;17) or promyelocytic leukemia/retinoic acid receptor alpha (PML-RARα) mutation. Patients received 12 mg/m2/day idarubicin intravenously for 3 days and 100 mg/m2/day cytarabine for 7 days, plus 45 mg/m2/day ATRA. Clinical outcomes included complete remission (CR), relapse-free survival (RFS), overall survival (OS), and the secondary malignancy incidence during a 20-year follow-up. Results: The CR, 10-year RFS, and 10-year OS rates were 89.7%, 94.1%, and 73.8%, respectively, for all patients. The 10-year OS rate was 100% for patients that achieved CR. Subjects were classified according to the white blood cell (WBC) count in peripheral blood at diagnosis (low-risk, WBC < 10,000/mm3; high-risk, WBC ≥ 10,000/mm3). The low-risk group had significantly higher RFS and OS rates than the high-risk group, but the outcomes were not superior to the current standard treatment (arsenic trioxide plus ATRA). Toxicities were similar to those observed with anthracycline plus ATRA, and higher than those observed with arsenic trioxide plus ATRA. The secondary malignancy incidence after APL treatment was 2.7%, among the 75 patients that achieved CR, and 5.0% among the 40 patients that survived more than 5 years after the APL diagnosis. Conclusions Adding cytarabine to anthracycline plus ATRA was not inferior to anthracycline plus ATRA alone, but it was not comparable to arsenic trioxide plus ATRA. The probability of secondary malignancy was low.

Background: Given the expanding clinical use of poly(adenosine diphosphate [ADP]-ribose) polymerase inhibitors (PARPis), there is a significant need for optimal strategies with which to treat patients whose cancer progresses while using a PARPi. However, the treatment consensus after PARPi has not been established. The aim of the Korean Gynecologic Oncology Group (KGOG) 3056/NIRVANA-R trial is to investigate the efficacy of niraparib in combination with bevacizumab as a maintenance therapy in platinum-sensitive ovarian cancer patients who were previously treated with a PARPi. Methods The KGOG 3056/NIRVANA-R is a multi-centre, investigator-initiated, single-arm, phase II trial of patients with platinum-sensitive recurrent ovarian cancer recruited from seven KGOG sites. This study included patients with platinum-sensitive recurrent epithelial ovarian cancer who received at least 2 previous courses of platinum-containing therapy and had been treated with a PARPi. Mucinous histology type was excluded. Patients who had responded to the last platinum regimen (either complete or partial response) were eligible to participate in this study. Forty-four patients will be recruited. All enrolled patients are treated with niraparib and bevacizumab for maintenance therapy until disease progression, unacceptable toxicity, or withdrawal of patient consent. The primary endpoint of the study is 6-month progression-free survival rate. Accrual is expected to be completed in 2022, followed by presentation of results in 2023.

In this article, we report two cases of pectoralis major muscle flap for a fourth degree burn on the shoulder in patients for whom performing latissimus dorsi (LD) flap was difficult. The operation site healed without complications, such as flap necrosis or inflammation. The pectoralis major muscle flap, which uses the thoracoacromial artery as a pedicle, provides sufficient muscle size and bulkiness to cover the large shoulder defects. Therefore, owing to these advantages, the pectoralis major muscle flap can be a great alternative option for shoulder reconstruction when the LD flap cannot be performed.

It is challenging to determine which beneficiary recipient vessel to use when performing microsurgery. The condition of the previous recipient vessel controls the outcome, when using the same recipient vessel inevitably in reoperation. In this case, we reconstructed the foot by reusing anterior tibial artery as a recipient vessel. A partial defect occured in patient who underwent reconstruction of the right foot with latissimusi dorsi free flap. We reconstructed the defect using anterolateral thigh (ALT) free flap. When reconstructing with ALT free flap, we planned to reuse ATA. The operation site was healed without complications. If the transplanted flap and the condition of the recipient vessels are reliable, surgeons can consider reusing the recipient vessels during reoperation.

Selecting an appropriate recipient vessel is the first step in microsurgery for lower extremity reconstruction. As for the second attempt, finding an appropriate recipient vessel will be more challenging because the best option has already been used. In this case, we performed an anterolateral thigh free flap on the anterior tibial artery, which was previously used for microsurgery. Precise pre- and intraoperative examinations were performed to confirm the reliability of the vessel for reuse. During surgery, we revealed that anterograde arterial flow was dominant over the retrograde flow and performed anterograde arterial anastomosis. The surgical site was healed without flap necrosis. Retrograde arterial anastomosis is typically performed when the recipient vessel is reused. However, in this case, we used an anterograde arterial anastomosis. If an accurate evaluation is performed before surgery, reusing the recipient vessel by anterograde arterial anastomosis for microsurgery may be a great option.